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Background
Molecular study is considered to be the gold standard
for single gene disorders. For Lysosomal storage disorders
(LSDs), plethora of literature report indicates the use of
lysosomal enzyme activity in uncultured chorionic villus
sample (CV), cultured chorionic villus (CT) or cultured
amniotic fluid cells (AF) as a reliable tool for prenatal
diagnosis (PD) followed by mutation study as a confirma-
tion where mutation is known and/or unequivocal enzyme
activity is observed. Very few studies are available from
India with anecdotal reports using either molecular meth-
ods or enzyme study in PD of LSDs. Nonetheless consid-
ering the reported prevalence of 1:5,000-7,000 live birth
and limited availability of therapeutic option PD remains
the only preventable cure for storage disorders.
Aim
To establish prenatal diagnosis of LSDs and demonstrate
the reliable use of lysosomal enzyme study for prenatal
diagnosis.
Material and method
One hundred twenty pregnancies with confirmed index
case of LSD were selected for lysosomal enzymes study
from CV, CT and AF. Written consent was obtained
from guardian of the study subjects.
Results
Of 120 pregnancies, 57 (47.5%) were normal, 8 (6.66%)
had an intermediate enzyme values and rest 55 (45.8%)
were found to be affected with specific LSD. From the
affected fetuses, 11 (9.1%) were affected with MPS-I,
2 (1.7%) with MPS-II, 1 (0.8%) with MPS-IIIA, 1 (0.8%)
with MPS-IIIB, 4 (3.4%) with MPS-IVA, 2 (1.7%) with
MPS-VI, 7 (5.8%) with GM-1 gangliosidosis, 1 (0.8%)
with Gaucher, 3 (2.5%) with Tay-sachs, 2 (1.7%) with
Sandhoff, 1 (0.8%) with NPD-A/B, 1 (0.8%) with MLD,
9 (7.5%) with Krabbe, 4 (3.4%) with Pompe, 2 (1.7%)
with Batten and 4 (3.4%) with Mucolipidosis-II/III. All
affected fetuses have shown very low enzyme activity
(~0-15% of normal mean). We have also identified 8
(6.66%) pregnancies with intermediate enzyme activity
(~50% of mean) this includes 3 (2.5%) fetuses were car-
rier with Sandhoff, 2 (1.7%) with Mucolipidosis-II/III,
each one (0.8% for each) with MLD, NPD-A/B and
Tay-sachs disease. Except one case of MPS-IVA who
was found to have carrier (~30% enzyme activity) during
prenatal diagnosis was found to be affected with MPS-
IVA after delivery.
Conclusions
Prenatal diagnosis of LSDs can be made with equal
sensitivity and specificity of the molecular study using
CV, CT and AF. Nonetheless carrier identification needs
to be confirmed by molecular analysis.
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